Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALM-PAH phase 3 trial of once-daily treprostinil palmitil inhalation powder in pulmonary arterial hypertension
jRCT2031260185Phase 3Recruiting
- Sponsor
- Insmed Incorporated
- Start
- Jul 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Treprostinil Palmitil Inhalation Powder with Placebo (2 arms). Primary endpoint: Change in 6-Minute Walk Distance measured 1 to 3 hours post-dose from baseline at Week 24. Started Jul 2026; status: recruiting.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2031260185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260185.